Tofacitinib citrate

CAS: 540737-29-9

Rif. IN-DA00DDVS

Informazioni sul prodotto

• Nome: Tofacitinib citrate
• Sinonimi: [u'CP 690,550', u'CP 690550', u'CP-690,550', u'CP-690550', u'CP690550', u'tasocitinib', u'tofacitinib', u'Xeljanz', u'540737-29-9', u'Tasocitinib citrate', u'Xeljanz', u'Tofacitinib (CP-690550) Citrate', u'UNII-O1FF4DIV0D', u'CP-690550 citrate', u'O1FF4DIV0D', u'CHEBI:71197', u'CP-690550-10', u'CP-690,550-10', u'3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate', u'CP 690550 citrate', u'Tofacitinib citrate [USAN]', u'Xeljanz Xr', u'citro; tofacitinib', u'3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate', u'3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate salt', u'3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl}-amino]-piperidin-1-yl)-3-oxo-propionitrile citrate salt', u'CEP-18770(Delanzomib)', u'MLS006010058', u'SCHEMBL1374185', u'CHEMBL2103743', u'Tofacitinib citrate (JAN/USAN)', u'DTXSID80202404', u'EX-A204', u'Tofacitinib citrate(CP690550)', u'SYIKUFDOYJFGBQ-YLAFAASESA-N', u'C22H28N6O8', u'AOB87768', u'HY-40354A', u's5001', u'AKOS022178222', u'CP-690550 - Tofacitinib citrate', u'Tofacitinib citrate, >=98% (HPLC)', u'API0017273', u'CS-0928', u'PB31590', u'1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)- beta-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)', u'AC-25004', u'AS-19392', u'BC600313', u'SC-12808', u'SMR004701220', u'AB0033779', u'AX8223835', u'Tofacitinib citrate (CP-690550 citrate)', u'ST24050181', u'X7518', u'D09783', u'Q-3287', u'(3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-?-oxo-1-piperidinepropanenitrile citrate', u'(3R,4R)-4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidine propanenitrile 2-hydroxy-1,2,3-propanetricarboxylate', u'(3R,4R)-4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-1-PIPERIDINEPROPANENITRILE CITRATE SALT', u'1-PIPERIDINEPROPANENITRILE,4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-,(3R,4R)-,2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE(1:1)', u'2-hydroxypropane-1,2,3-tricarboxylic acid;3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile', u'3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile mono citrate salt', u'3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile Mono Citrate Salt', u'Xeljanz (TN)', u'tofacitinib citric acid', u'CP-690550', u'540737-29-9 (citrate)', u'MFCD11616529', u'ACN-037647', u'CID10174505', u'CID 10174505', u'CP690550', u'Tofacitinib citrate, 99% - 10MG 10mg', u'C16-H20-N6-O.C6-H8-O7', u'CP 690550', u'CP-690550 Citrate (Tofacitinib Citrate)', u'A4135', u'CP-690,550', u'CP 690550-10'], (3R,4R)-1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3-propanetricarboxylate, (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile 2-Hydroxy-1,2,3-propanetricarboxylate, 1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-4-Ylamino)-Beta-Oxo-, (3R,4R)-, 2-Hydroxy-1,2,3-Propanetricarboxylate (1:1), 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1), Cp 690500-10, Cp 690550-10, Tasocitinib citrate, Tofacitnib Citrate, Xeljanz, Xeljanz XR
• Marchio: Indagoo

Proprietà chimiche

• Peso molecolare: 504.4931
• Formula: C₂₂H₂₈N₆O₈
• Purezza: 99%
• Colore/Forma: Solid
• InChI: InChI=1S/C16H20N6O.C6H8O7/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t11-,13+;/m1./s1
• InChI key: SYIKUFDOYJFGBQ-YLAFAASESA-N